NCT02728219已完成不适用
A Prospective Randomized Trial Comparing Treatment of Recurrent HCC With Repeat Hepatectomy,and Transcatheter Arterial Chemoembolization (TACE) With AFP Conversion
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- overall survival
研究概览
简要总结
The purpose of this study is to compare the treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion.
详细描述
Though many HCC patients have been benefited from hepatectomy treatment, still the high recurrence rate after the hepatectomy led to limited effectiveness.
This is the first study in same case system on comparison of effectiveness among repeat hepatectomy, and TACE with AFP conversion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •via clinical diagnosis and confirm it is early recurrent liver cancer with AFP conversion, and not accept any anticancer treatment.
- •age:18-70years
- •better liver function (Child-Pugh,class A or B)
排除标准
- •reject to attend;
- •impossible to come to our hospital for physical examination regularly.
- •cancer epitome、seed focus、lymph node or distant metastasis
- •Blood clotting function hindrance;
- •serious heart、lung、kidney disease
结局指标
主要结局
overall survival
时间窗: 3 years
次要结局
未报告次要终点
研究者
ShenFeng
vice president of the Eastern Hepatobiliary Surgery Hospotal
Eastern Hepatobiliary Surgery Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
STOP HCC: Mailed HCV Treatment Outreach Program for HCC PreventionHepatitis CHepatoCellular CarcinomaNCT03706742University of Texas Southwestern Medical Center12,386
已完成
不适用
A Study of HCC High Risk Group Using Two Surveillance ToolsHCCNCT02675920Seoul National University Hospital139
Unknown
2 期
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaBile Duct CancerIntrahepatic CholangiocarcinomaNCT03086993Delcath Systems Inc.295
Unknown
不适用
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular CarcinomaHepatocellular CarcinomaNCT05053386Zhejiang Cancer Hospital186
已完成
3 期
Surgery or Chemoradiation for Esophageal CancerEsophageal CancersNCT01032967Chinese University of Hong Kong40
